Supplements

Modified Sini Powder (MSNP) reduces depressive symptoms in postoperative non-small cell lung cancer patients with mild-to-moderate depression

This protocol describes a multicenter, randomized, double-blind, placebo-controlled trial evaluating MSNP for postoperative mild-to-moderate depression in NSCLC patients. The primary outcome is the total effective rate at 6 weeks, defined as a ≥25% reduction in the 17-item Hamilton Depression Rating Scale score from baseline. The study aims to provide robust clinical evidence and explore multi-omics mechanisms.

1 min read•Updated Jul 7, 2026•1 RCTs•View structured evidence →
Evidence Score44/100
Human RCT☆☆☆☆☆
Meta-analysis☆☆☆☆☆
Mechanism☆☆☆☆☆
Safety☆☆☆☆☆
Confidencelow

This article is automatically generated from the structured evidence profile behind the claim above. Scores reflect the quality and quantity of available research, not clinical advice.

Modified Sini Powder (MSNP) reduces depressive symptoms in postoperative non-small cell lung cancer patients with mild-to-moderate depression The current body of evidence comprises 1 study, including 1 randomized controlled trial. EvidenceHub rates the overall confidence at 44/100 (low).

The Claim

Modified Sini Powder (MSNP) reduces depressive symptoms in postoperative non-small cell lung cancer patients with mild-to-moderate depression

This conclusion is most relevant to: Postoperative non-small cell lung cancer patients with mild-to-moderate depression (n=468 across nine tertiary medical centers).

What the Research Shows

The conclusion draws on 1 linked study. Highlights from the cited literature:

  • ▸Modified sini powder for the management of postoperative depression in non-small cell lung cancer patients: a multicenter, randomized, double-blind, placebo-controlled trial protocol. (Frontiers in pharmacology, 2026) —

How It Works

The proposed biological pathway:

  • ▸MSNP modulates inflammatory cytokines and HPA axis hormones
  • ▸Alters neurotransmitter levels and brain-derived neurotrophic factor
  • ▸Changes serum metabolomics and gut microbiota profiles
  • ▸Result: Multi-target and multi-pathway alleviation of depressive symptoms

Who Might Benefit

Evidence fit by population:

  • ▸Postoperative non-small cell lung cancer patients with mild-to-moderate depression (n=468 across nine tertiary medical centers)

Limitations & Caveats

Important context when interpreting this evidence:

  • ▸Protocol only; no results yet reported, so efficacy and safety remain unconfirmed
  • ▸Potential placebo effect due to subjective nature of depression rating scales
  • ▸Generalizability limited to Chinese tertiary medical centers and mild-to-moderate depression

References

  1. 1.Jin Y, Wang J, Li H, Fan M, Zhang S, Lin B, Mi Y, Gong C, Gu P, Xu K, Zhao B, Lang J, Chen M. “Modified sini powder for the management of postoperative depression in non-small cell lung cancer patients: a multicenter, randomized, double-blind, placebo-controlled trial protocol..” Frontiers in pharmacology, 2026. PMID: 42403716 DOI: 10.3389/fphar.2026.1805554
Disclaimer: This article is auto-generated from structured research data for educational purposes only and is not medical advice. Evidence scores reflect the quality and quantity of available research, not clinical recommendations. Always consult a healthcare professional before starting any supplement or intervention.